Overview

Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas

Status:
Completed
Trial end date:
2019-02-20
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if a chemotherapy combination called modified Folfirinox (or mFolfirinox), followed by a combination of gemcitabine and radiation therapy, followed by surgery, can help to control pancreatic cancer. The safety of this treatment will also be studied. mFolfirinox consists of 5-FU, oxaliplatin, and irinotecan. These 3 drugs, along with gemcitabine, are each designed to block the growth of cancer cells, which may lead to cancer cell death.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Fluorouracil
Gemcitabine
Irinotecan
Oxaliplatin
Pancreatin
Pancrelipase